

Product Name: Cordycepin Revision Date: 01/10/2021

Product Data Sheet

Cordycepin

Cat. No.: N2808

CAS No.: 73-03-0

Formula: C10H13N5O3


M.Wt: 251.24

Synonyms:

Target: Natural Products

Pathway:

Storage: Store at -20°C



Solvent & Solubility

insoluble in EtOH; insoluble in H2O; \geq 10.3 mg/mL in DMSO

In Vitro

| Preparing Stock Solutions | Solvent Concentration | 1mg | 5mg | 10mg |
|---------------------------|-----------------------|-----------|------------|------------|
| | 1 mM | 3.9803 mL | 19.9013 mL | 39.8026 mL |
| | 5 mM | 0.7961 mL | 3.9803 mL | 7.9605 mL |
| | 10 mM | 0.3980 mL | 1.9901 mL | 3.9803 mL |

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Reacting conditions:

| Shortsummary | | |
|---------------------------|----------------------|--|
| IC ₅₀ & Target | | |
| | Cell Viability Assay | Control of the Contro |
| | Cell Line: | HeLa cells |
| | Preparation method: | The solubility of this compound in DMSO is >10.3 mg/mL. General tips for |
| In Vitro | | obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes |
| | | and/or shake it in the ultrasonic bath for a while. Stock solution can be stored |
| | | below -20°C for several months. |

25 µg/ml, 30 min

| | Applications: | Cordycepin (25 µg/ml) suppressed the labeling of messenger RNA in HeLa | | | |
|---------|--|---|--|--|--|
| | | cells. Cordycepin inhibited NO production in a dose-dependent manner up to | | | |
| | | 30 μg/ml. In RAW 264.7 cells, treatment with cordycepin decreased | | | |
| | | LPS-induced synthesis of iNOS protein in a dose-dependent manner. | | | |
| | | Cordycepin significantly decreased the mRNA levels of TNF-α induced by LPS | | | |
| | 210 | in a dose-dependent manner. Cordycepin (20 µg/ml) inhibited LPS-mediated | | | |
| | A Partition of the Control of the Co | ΙκΒα phosphorylation in a dose-dependent manner in LPS-induced | | | |
| | | macrophage cell. Cordycepin decreased the phosphorylation level of p38 and | | | |
| | | Akt in LPS-stimulated cells in a concentration-dependent manner. | | | |
| | Animal experiment | | | | |
| | Animal models: | Mice bearing B16 melanoma (B16-BL6) cells, | | | |
| | Dosage form: | Oral administration, 15 mg/kg per day for 2 weeks | | | |
| | Applications: | Oral administration of cordycepin (15 mg/kg per day) for 2 weeks significantly | | | |
| | | reduced the wet weight of the primary tumour lump, without any loss of | | | |
| | 310 | bodyweight or systemic toxicity. Cordycepin (15 mg/kg per day) inhibited the | | | |
| | OE | tumour enlargement in the right thigh inoculated with B16-BL6 cells premixed | | | |
| In Vivo | Control of the Contro | with extracellular matrix. In hematogenic metastatic mouse model bearing | | | |
| | | B16-BL6 melanoma cells, 3-hour exposure to various concentrations of | | | |
| | | cordycepin (0.3, 1 and 3 $\mu g/ml$) dose-dependently reduced the number of | | | |
| | | nodules formed in lung at 15 days after the tumor injection. Cordycepin did not | | | |
| | | influence the growth curve of B16-BL6 cells at concentrations up to 3 μg/ml. | | | |
| | Other notes: | Please test the solubility of all compounds indoor, and the actual solubility may | | | |
| | | slightly differ with the theoretical value. This is caused by an experimental | | | |
| | ~10 | system error and it is normal. | | | |
| | 1 July 200 | | | | |

Product Citations

See more customer validations on www.apexbt.com.

References

- [1]. Penman S, Rosbash M, Penman M. Messenger and heterogeneous nuclear RNA in HeLa cells: differential inhibition by cordycepin[J]. Proceedings of the National Academy of Sciences, 1970, 67(4): 1878-1885.
- [2]. Kim H G, Shrestha B, Lim S Y, et al. Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-κB through Akt and p38 inhibition in RAW 264.7 macrophage cells[J]. European journal of pharmacology, 2006, 545(2): 192-199.
- [3]. Yoshikawa N, Nakamura K, Yamaguchi Y, et al. Antitumour activity of cordycepin in mice[J]. Clinical and Experimental Pharmacology and Physiology, 2004, 31(s2).
- [4]. Nakamura K, KONOHA K, YOSHIKAWA N, et al. Effect of cordycepin (3'-deoxyadenosine) on hematogenic lung metastatic model

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE BIO

APEBIO

ARE BIO

APE BIO